LEAP THERAPEUTICS INC (LPTX) Stock News

The trading volume of these stocks is deviating from the norm in today's session.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline

While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints.

Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes

Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer. Gastric cancer studies end due to lack of PFS benefit.

These stocks are moving in today's session

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

The market is filled with gapping stocks in Tuesday's session.

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared...

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics Reports Third Quarter 2024 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024

LPTX stock results show that Leap Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Leap Therapeutics (NASDAQ:LPTX) just reported results for the second quarter of...

Leap Therapeutics Reports Second Quarter 2024 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024

LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Leap Therapeutics Reports First Quarter 2024 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Leap Therapeutics Announces $40 Million Private Placement

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023

LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Leap Therapeutics (NASDAQ:LPTX) just reported results for the fourth quarter of...

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Leap Therapeutics Reports Third Quarter 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis